Internship
Develops software as prescription medical treatments
$22/hr
New York, NY, USA
This is a hybrid internship requiring in-office presence on Wednesdays and Fridays.
Get referrals →
You have ways to get a Click Therapeutics referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they can be used independently or alongside traditional treatments. The applications undergo rigorous testing through randomized controlled trials to ensure they are safe and effective before seeking FDA clearance to be marketed as class II medical devices. Revenue is generated from physicians who prescribe these apps and from payers who reimburse for them. Click Therapeutics also collaborates with other healthcare companies, such as Boehringer Ingelheim, to enhance their offerings, exemplified by a significant partnership aimed at treating schizophrenia. The company's goal is to provide effective digital solutions for unmet medical needs, continuously improving their applications using real-world evidence.
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$161.6M
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Arrangement
Stock Options
Performance Bonus
Fertility Treatment Support
Professional Development Budget
Commuter Benefits
What You Should Know: – Click Therapeutics, Inc. (“Click”), a leader in the rapidly evolving field of prescription medical treatments, encompassing both prescription digital therapeutics (PDTs) and software-enhanced drug™ therapies has received FDA marketing authorization for CT-132, the first prescription digital therapeutic specifically indicated for the preventive treatment of episodic migraine in adults aged 18 and older.– The FDA granted a De Novo Classification Request for CT-132, signifying the novel nature of this digital intervention. This PDT is intended for adjunctive use alongside existing acute and/or other preventive migraine treatments, offering patients an additional tool in their management strategy.CT-132 Prescription Digital TherapeuticThe CT-132 prescription digital therapeutic is indicated for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and / or other preventive treatments for migraine. The FDA’s decision was primarily based on compelling data from the pivotal ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900) study. This study evaluated CT-132 in patients already taking standard-of-care prescription migraine medications (including acute, first-line preventive, and second-line preventive treatments) and successfully met its primary endpoint of significantly reducing monthly migraine days.ReMMi-D and ReMMiD-C StudiesFurther supporting the authorization were results from the ReMMiD-C bridging study (NCT06004388)
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced its investment in Click Therapeutics, a leader in prescription digital therapeutics ...
Click Therapeutics launches Software-Enhanced Drug therapies.
NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.
PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).